Target Name: OR1E2
NCBI ID: G8388
Review Report on OR1E2 Target / Biomarker Content of Review Report on OR1E2 Target / Biomarker
OR1E2
Other Name(s): OR1E7 | Olfactory receptor, family 1, subfamily E, member 7 | olfactory receptor OR17-17 | OR17-136 | olfactory receptor family 1 subfamily E member 2 | OTTHUMP00000115810 | OR17-93 | Oolfactory receptor, family 1, subfamily E, member 4 | Olfactory receptor family 1 subfamily E member 2 | olfactory receptor 17-93/17-135/17-136 | OR1E2_HUMAN | Olfactory receptor OR17-3 | olfactory receptor, family 1, subfamily E, member 4 | Olfactory receptor 1E2 | olfactory receptor OR17-3 | OR1E4 | Olfactory receptor, family 1, subfamily E, member 2 | Olfactory receptor OR17-17 | Olfactory receptor 1E4 | olfactory receptor 1E4 | Olfactory receptor 17-93/17-135/17-136 | olfactory receptor, family 1, subfamily E, member 7 | OST529 | OR17-135

OR1E2: A Potential Drug Target and Biomarker

OR1E2, short for OL Wisconsin, E2, and 220, is a gene that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. OR1E2 is a non-coding RNA molecule that has has been shown to play a role in the regulation of cellular processes, including cell adhesion, migration, and survival.

The OR1E2 gene was first identified in the late 1990s using transcriptional analysis of RNA isolated from human leukemia cell lines. OR1E2 was found to be highly expressed in these cells, and experiments have since shown that it is involved in the regulation of various cellular processes, including cell adhesion, migration, and survival.

One of the most promising aspects of OR1E2 is its potential as a drug target. OR1E2 has been shown to play a role in the regulation of the PI3K/Akt signaling pathway, a pathway that is involved in the regulation of cellular processes that are important for cancer growth, survival, and angiogenesis. This pathway is a target for a variety of drugs, including inhibitors of the Akt kinase, which is a key component of the PI3K/Akt signaling pathway.

OR1E2 has also been shown to be involved in the regulation of the TGF-β signaling pathway, a pathway that is involved in the regulation of cell growth, differentiation, and survival. This pathway is a target for a variety of drugs, including inhibitors of the TGF-β receptor, which is a key component of the TGF-β signaling pathway.

In addition to its potential as a drug target, OR1E2 has also been shown to be a potential biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. OR1E2 has been shown to be expressed in a variety of tissues and cells. , including cancer cells, neurons, and immune cells. This suggests that it may be a useful biomarker for these diseases, and that its levels may be able to be used as a diagnostic marker.

OR1E2 has also been shown to play a role in the regulation of cellular processes that are important for the development and progression of neurodegenerative diseases. For example, studies have shown that OR1E2 is involved in the regulation of the expression of genes that are involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

In conclusion, OR1E2 is a gene that has the potential to be a drug target and biomarker for a variety of diseases. Its involvement in the regulation of cellular processes that are important for cancer growth, survival, and neurodegenerative diseases makes it a promising target for drug development. Further research is needed to fully understand the role of OR1E2 in these processes and to develop safe and effective drugs that can target it.

Protein Name: Olfactory Receptor Family 1 Subfamily E Member 2

Functions: Odorant receptor

The "OR1E2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OR1E2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

OR1E3 | OR1F1 | OR1F2P | OR1G1 | OR1I1 | OR1J1 | OR1J2 | OR1J4 | OR1K1 | OR1L1 | OR1L3 | OR1L4 | OR1L6 | OR1L8 | OR1M1 | OR1N1 | OR1N2 | OR1P1 | OR1Q1 | OR1S1 | OR1S2 | OR2A1 | OR2A1-AS1 | OR2A12 | OR2A14 | OR2A2 | OR2A20P | OR2A25 | OR2A4 | OR2A42 | OR2A7 | OR2A9P | OR2AE1 | OR2AG1 | OR2AG2 | OR2AJ1 | OR2AK2 | OR2AL1P | OR2AM1P | OR2AP1 | OR2AT4 | OR2B11 | OR2B2 | OR2B3 | OR2B6 | OR2C1 | OR2C3 | OR2D2 | OR2D3 | OR2F1 | OR2F2 | OR2G2 | OR2G3 | OR2G6 | OR2H1 | OR2H2 | OR2I1P | OR2J1 | OR2J2 | OR2J3 | OR2J4P | OR2K2 | OR2L13 | OR2L1P | OR2L2 | OR2L3 | OR2L5 | OR2L8 | OR2L9P | OR2M1P | OR2M2 | OR2M3 | OR2M4 | OR2M5 | OR2M7 | OR2Q1P | OR2S2 | OR2T1 | OR2T10 | OR2T11 | OR2T12 | OR2T2 | OR2T27 | OR2T29 | OR2T3 | OR2T33 | OR2T34 | OR2T35 | OR2T4 | OR2T5 | OR2T6 | OR2T7 | OR2T8 | OR2U1P | OR2V1 | OR2V2 | OR2W1 | OR2W1-AS1 | OR2W3 | OR2W5P